Research Analysts Offer Predictions for VYGR Q3 Earnings

Key Points

• Voyager Therapeutics reported a Q3 EPS of ($0.57), missing estimates by $0.09, with revenue of $5.20 million versus expectations of $9.50 million.
• Equity analysts from Leerink Partners have lowered their Q3 2025 EPS forecast for Voyager Therapeutics to ($0.55), down from ($0.45).
• Despite the recent setbacks, Voyager Therapeutics holds an average buy rating among analysts with a price target of $13.25.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings per share of ($0.55) for the quarter, down from their previous forecast of ($0.45). The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.23) EPS, FY2026 earnings at ($0.48) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at ($1.03) EPS.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. The company had revenue of $5.20 million during the quarter, compared to analysts' expectations of $9.50 million.

Separately, Wedbush reduced their target price on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $13.25.

Voyager Therapeutics Price Performance

VYGR traded down $0.05 on Monday, hitting $3.61. The company had a trading volume of 252,571 shares, compared to its average volume of 526,236. The company's fifty day moving average price is $3.24 and its 200 day moving average price is $3.60. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $8.27. The stock has a market cap of $199.97 million, a price-to-earnings ratio of -1.95 and a beta of 0.90.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC raised its position in Voyager Therapeutics by 53.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock valued at $204,000 after buying an additional 21,149 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Voyager Therapeutics during the 4th quarter worth approximately $746,000. Northern Trust Corp lifted its holdings in Voyager Therapeutics by 3.0% during the 4th quarter. Northern Trust Corp now owns 418,745 shares of the company's stock worth $2,374,000 after purchasing an additional 12,374 shares during the last quarter. CWM LLC raised its holdings in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock valued at $35,000 after acquiring an additional 9,376 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Voyager Therapeutics by 13.9% in the 4th quarter. Wellington Management Group LLP now owns 261,251 shares of the company's stock valued at $1,481,000 after acquiring an additional 31,882 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.